The prognostic value of circulating tumor markers in patients with hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034959

Enrollment

100

Registered

2024-08-26

Start date

2018-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22

Interventions

Group 1: HCC patients who underwent resection, TACE or MWA Group 2: Ppatients with nonmalignant liver disease, patients with tumors other than HCC and healthy donors

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with HCC

Exclusion criteria

Exclusion criteria: Infections (HBV, HCV, HIV), systemic diseases, IBD, post-transplantation status

Design outcomes

Primary

Measure	Time frame
Correlation between circulating tumor marker and recurrence-free survival (RFS) and overall survival (OS) in HCC patients four years after surgery	—

Secondary

Measure	Time frame
Short- and long-Term Dynamik of circulating tumor marker	—

Countries

Germany

Contacts

Public ContactMazen Juratli

Universitätklinikum Frankfurt, Klinik füt Allgemein-, Viszeral- und Transplantationschirurgie

Oncology.reseach.frankfurt@gmail.com00492518351403

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026